{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:52:25Z","timestamp":1793641945118,"version":"4.5.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008207","name":"AstraZeneca Canada Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008207","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ygyno.2025.03.022","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T15:47:24Z","timestamp":1742831244000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Comparative efficacy and safety of low-dose versus high-dose bevacizumab in ovarian cancer: An indirect treatment comparison"],"prefix":"10.1016","volume":"196","author":[{"given":"Jos\u00e9e-Lyne","family":"Ethier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cal","family":"Shephard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana P.","family":"Granados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikkita","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Qadeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Kasireddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir-Masoud","family":"Pourrahmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir Sohail","family":"Fazeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2025.03.022_bb0005","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.3390\/cancers14092230","article-title":"Worldwide burden, risk factors, and temporal trends of ovarian Cancer: a global study","volume":"14","author":"Huang","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ygyno.2025.03.022_bb0010","doi-asserted-by":"crossref","first-page":"12041","DOI":"10.3390\/ijms231912041","article-title":"Molecular biomarkers for the early detection of ovarian Cancer","volume":"23","author":"Zhang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","article-title":"Ovarian Cancer: an integrated review","volume":"35","author":"Stewart","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2022.04.021","article-title":"State of the science: contemporary front-line treatment of advanced ovarian cancer","volume":"166","author":"Hinchcliff","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0025","first-page":"73","article-title":"Current First-line Therapy for Ovarian Cancer: A Comprehensive Review","author":"Pierce","year":"2018","journal-title":"Obstet. Gynecol. Surv."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102298","article-title":"Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors","volume":"101","author":"Bartoletti","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0035","series-title":"Ovarian Cancer","author":"Arora","year":"2022"},{"key":"10.1016\/j.ygyno.2025.03.022_bb0040","series-title":"AVASTIN\u00ae (bevacizumab for injection), Canadian Product Monograph","year":"2023"},{"key":"10.1016\/j.ygyno.2025.03.022_bb0045","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0050","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian Cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0055","series-title":"Bevacizumab (Avastin) Ovarian Cancer - Final Recommendation","author":"Canadian Agency for Drugs and Technologies in Health","year":"2015"},{"key":"10.1016\/j.ygyno.2025.03.022_bb0060","first-page":"1","article-title":"Canadian Agency for Drugs and Technologies in health. Provincial funding summary. Bevacizumab (Avastin) for ovarian","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2025.03.022_bb0065","series-title":"Prescription Drug Insurance. Find out whether a drug is covered","author":"R\u00e9gie de l'\u2019assurance maladie","year":"2024"},{"key":"10.1016\/j.ygyno.2025.03.022_bb0070","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian Cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0075","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0080","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.critrevonc.2015.01.012","article-title":"Bevacizumab: A dose review","volume":"94","author":"Falk","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0085","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0090","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0095","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11060-016-2195-9","article-title":"A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma","volume":"129","author":"Weathers","year":"2016","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0100","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0105","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.ygyno.2025.03.022_bb0110","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clin. Res. ed)."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0115","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"Chapter 8: Assessing risk of bias in a randomized trial","author":"Higgins","year":"2023"},{"key":"10.1016\/j.ygyno.2025.03.022_bb0120","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1741-7015-12-93","article-title":"A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer","volume":"12","author":"Cope","year":"2014","journal-title":"BMC Med."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0125","series-title":"Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis","author":"Wells","year":"2009"},{"key":"10.1016\/j.ygyno.2025.03.022_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting Meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0135","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejca.2016.09.036","article-title":"Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial","volume":"70","author":"Rouzier","year":"2017","journal-title":"Eur. J. Cancer (Oxford, England\u202f: 1990)"},{"key":"10.1016\/j.ygyno.2025.03.022_bb0140","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/ijgc-2019-000256","article-title":"Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer","volume":"29","author":"Garcia Garcia","year":"2019","journal-title":"Int. J. Gynecol. Cancer\u202f: Off. J. Int. Gynecol. Cancer Soc."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0145","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ygyno.2019.03.256","article-title":"An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC\/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor","volume":"153","author":"Gore","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0150","first-page":"1003","article-title":"Therapeutic effect of bevacizumab combined with paclitaxel and carboplatin on recurrent ovarian cancer","volume":"24","author":"Cong","year":"2019","journal-title":"J. BUON\u202f: Offi. J. Balkan Union Oncol."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0155","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ygyno.2021.01.028","article-title":"The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: a systematic review and meta-analysis","volume":"161","author":"Liu","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0160","doi-asserted-by":"crossref","first-page":"680","DOI":"10.4103\/ijmr.IJMR_1160_19","article-title":"Anti-angiogenic therapy in ovarian cancer: current situation & prospects","volume":"154","author":"Liu","year":"2021","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0165","article-title":"Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer","volume":"2019","author":"Coleridge","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0170","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1757-2215-7-57","article-title":"Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review","volume":"7","author":"Aravantinos","year":"2014","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0175","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-051037","article-title":"Role of maintenance strategies in advanced epithelial ovarian cancer: a systematic review, network meta-analysis and cost-effectiveness analysis protocol","volume":"11","author":"Hu","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.ygyno.2025.03.022_bb0180","doi-asserted-by":"crossref","first-page":"10703","DOI":"10.18632\/oncotarget.12926","article-title":"Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2025.03.022_bb0185","first-page":"1","article-title":"Avastin (bevacizumab) [product information]","author":"Roche Pharma","year":"2023","journal-title":"European Med. Agency Website."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0190","series-title":"Public Summary Document for Bevacizumab","author":"The Pharmaceutical Benefits Scheme","year":"2013"},{"key":"10.1016\/j.ygyno.2025.03.022_bb0195","series-title":"AVASTIN (bevacizumab) [package insert]","author":"Genentech Inc.","year":"2018"},{"key":"10.1016\/j.ygyno.2025.03.022_bb0200","series-title":"AVASTIN [Product information]","author":"Hoffmann-La Roche Limited","year":"2023"},{"key":"10.1016\/j.ygyno.2025.03.022_bb0205","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ygyno.2021.05.018","article-title":"Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: a review","volume":"162","author":"Alvarez Secord","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.03.022_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.951","article-title":"Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and\/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial","volume":"31","author":"Colombo","year":"2020","journal-title":"Ann. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825000915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825000915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:27:34Z","timestamp":1777955254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825000915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":42,"alternative-id":["S0090825825000915"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.03.022","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy and safety of low-dose versus high-dose bevacizumab in ovarian cancer: An indirect treatment comparison","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}